High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy
- 1 September 1979
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 2 (3), 175-180
- https://doi.org/10.1007/bf00258291
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- POSSIBLE NEW APPROACH TO TREATMENT OF METASTATIC BREAST-CANCER - MASSIVE DOSES OF MEDROXYPROGESTERONE ACETATE1978
- Norethisterone acetate in the treatment of advanced breast cancerEuropean Journal of Cancer (1965), 1976
- Massive-dose progestational therapy in oncology (medroxyprogesterone). Preliminary results.1976
- RESPONSE TO MEDROXYPROGESTERONE ACETATE (NSC-26386) AS SECONDARY HORMONE THERAPY FOR METASTATIC BREAST-CANCER IN POSTMENOPAUSAL WOMEN1976
- A clinical trial of megestrol acetate in advanced breast cancerCancer, 1974
- Norethisterone acetate (SH420) in advanced breast cancerCancer, 1973
- Clinical trial of Δ1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer:A report of the cooperative breast cancer groupCancer, 1969
- Treatment of Breast Cancer with Medroxyprogesterone AcetateAnnals of Internal Medicine, 1968
- Hormonal therapy in cancer of the breast.XXIV. Effect of corticosterone or medroxyprogesterone acetate on clinical course and hormonal excretionCancer, 1967
- Progestin therapy of breast cancer: comparison of agents.BMJ, 1967